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Abstract
Objectives: There	is	limited	clinical	evidence	for	comparison	between	oxcarbazepine	
(OXC)	and	eslicarbazepine	acetate	(ESL)	in	terms	of	tolerability,	or	how	to	execute	the	
change	from	OXC	to	ESL.	We	report	the	process	of	transitioning	patients	with	focal	
epilepsy	from	previous	OXC	treatment	to	ESL	due	to	tolerability	problems.	The	ration-
ale	for	change	from	OXC	is	reported,	and	the	outcome	with	respective	to	this	rationale	
is	analyzed	in	terms	of	tolerability	and	efficacy.
Materials and Methods: The	subjects	were	transitioned	overnight	from	OXC	to	ESL	in	
a	hospital	 inpatient	setting.	An	evaluation	of	the	effects	of	the	transition	was	made	
after	1	and	3	months.	All	adverse	events	(AEs)	were	recorded	following	the	transition	
period.	Subjects	were	classified	by	outcome	in	terms	of	AEs.
Results: Twenty-	three	subjects	were	transitioned	from	OXC	to	ESL.	Fifteen	patients	
OXC-	related	AEs	reduced	significantly	after	transition.	Particularly,	most	of	(93%)	the	
AEs	presented	in	the	morning	resolved	after	transition	to	ESL.	No	patient	had	an	in-
crease	in	seizure	frequency	following	the	transition.	The	incidence	of	ESL-	related	AEs	
was	39%	at	1	month	and	13%	at	3	month	follow-	up;	however,	all	patients	continued	
ESL	throughout	the	study	period.
Conclusions: This	study	demonstrates	that	patients	suffering	from	OXC-	related	AEs	
improve	in	terms	of	tolerability	after	a	switch	to	ESL	with	maintaining	seizure	control.	
This	improvement	is	more	pronounced	if	the	OXC-	related	AEs	are	most	evident	fol-
lowing	morning	dosing	of	OXC.	Transition	can	be	 safely	executed	 in	an	outpatient	
setting.
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1  | INTRODUCTION
Epilepsy	has	an	annual	incidence	of	about	50	per	100,000	and	prev-
alence	 between	 5	 and	 10	 per	 1,000	 (Sander,	 2003).	 Monotherapy	
with	an	antiepileptic	drug	(AED)	is	sufficient	to	achieve	seizure	con-
trol	without	intolerable	adverse	events	(AEs)	approximately	in	60%	of	
patients	(Stephen	&	Brodie,	2012).	AEs	related	to	AEDs	impact	nega-
tively	on	health-	related	quality	of	life,	cause	a	significant	source	of	dis-
ability,	and	may	lead	to	low	adherence	to	the	treatment	or	treatment	
discontinuation	(Stephen	&	Brodie,	2012).
In	adults	(>18	years),	oral	eslicarbazepine	acetate	(ESL)	is	approved	
in	the	EU	as	an	adjunctive	therapy	with	partial	onset	seizures	with	or	
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without	secondarily	generalization	and	in	the	US	as	a	monotherapy	or	
adjunctive	 treatment	 of	 partial-	onset	 seizures	 (Aptiom®;	Zebinix®).	
ESL	is	a	third-	generation	member	of	the	dibenzazepine	family,	which	
also	includes	carbamazepine	(CBZ)	and	oxcarbazepine	(OXC;	Keating,	
2014;	 Zaccara,	 Giovanelli,	 Cincotta,	 &	 Verrotti,	 2015).	 Blockade	 of	
voltage-	gated	 sodium	 channel	 (VGSC)	 is	 the	 proposed	 mechanism	
of	action	 for	CBZ,	OXC,	and	ESL	 (Keating,	2014),	but	ESL	has	been	
shown	 to	have	a	modulating	action	and	 inhibits	 the	 slow	activation	
of	VGSC	 (Hebeisen	et	al.,	2015)	and	also	an	effect	on	Cav3.2T-	type	
Ca2+	channels	(Doeser	et	al.,	2015).	ESL	is	a	prodrug	that	is	metabo-
lized	 to	 its	major	 active	metabolite	 eslicarbazepine	 (S-	licarbazepine)	
and	to	the	minor	active	metabolites	(R)-	licarbazepine	and	OXC,	which	
are	mainly	eliminated	by	renal	excretion	(both	unchanged	and	glucuro-
nide	conjugate	forms;	Keating,	2014).	Half-	life	terminal	elimination	of	
ESL	in	plasma	concentrations	varies	between	20–24	hr	allowing	once-	
daily	administration	regimen	(Perucca	et	al.,	2011).	Maximum	plasma	
concentrations	 of	 ESL	were	 reached	 in	median	 2.0–2.5	hr	 (Almeida	
&	Soares-	Da-	silva,	2004).	Steady	state	is	reached	in	4–5	days	(Elger,	
Halász,	Maia,	Almeida,	&	Soares-	Da-	silva,	2009).
Eslicarbazepine	 acetate	 is	 efficacious	 and	 well	 tolerated	 as	 ad-
junctive	therapy	in	drug-	resistant	focal	epilepsies	at	doses	of	800	and	
1,200	mg	once-	daily	 (Ben-	Menachem	et	al.,	2010;	Elger	et	al.,	2009;	
Gil-	Nagel,	 Lopes-	Lima,	Almeida,	Maia,	&	 Soares-	Da-	silva,	 2009;	Gil-	
Nagel	et	al.,	2013;	Sperling	et	al.,	2015).	Dizziness,	vertigo,	abnormal	
coordination,	 ataxia,	 diplopia,	 fatigue,	 somnolence,	 and	 headache	
are	most	often	reported	and	frequent	AEs	in	controlled	clinical	trials	
(Sperling	et	al.,	2015)	and	to	a	 lesser	degree	when	used	as	 the	only	
adjunctive	AED	(Holtkamp,	McMurray,	Bagul,	Sousa,	&	Kockelmann,	
2016).	It	was	noted	in	one	study	that	switching	from	OXC	to	ESL	(dose	
ratio	1:1)	was	associated	with	better	tolerability	during	ESL	treatment	
(Villanueva	et	al.,	 2014).	Recent	meta-	analysis	 compared	 the	 tolera-
bility	of	ESL,	OXC,	and	lacosamide	(LCM)	showing	that	patients	with	
OXC	withdrew	from	the	treatment	more	frequently	than	patients	with	
ESL	 or	 LCM	 (Zaccara,	Giovanelli,	Maratea,	 Fadda,	&	Verrotti,	 2013).	
Furthermore,	some	side-	effects	 (diplopia,	ataxia,	abnormal	coordina-
tion)	were	significantly	more	frequent	 in	OXC-	treated	patients	com-
pared	to	ESL	and	LCM.	ESL-	related	hyponatremia	varies	from	1.2%	to	
8.8%	between	different	 studies	 (Halasz	et	al.,	 2010;	Hufnagel	 et	al.,	
2013;	 Villanueva	 et	al.,	 2014;	 Zaccara	 et	al.,	 2013).	 The	 difference	
can	be	explained	in	terms	of	dosage	used,	population	characteristics,	
and	 cut-	off	 used	 to	 define	 hyponatremia.	 These	 data	 suggest,	 that	
ESL	might	share	similar	efficacy	compared	to	OXC,	but	with	less	AEs.	
Several	 dose-	dependent	 neurological	 AEs	 occur	 intermittently	 and	
appear	almost	always	a	few	hours	after	OXC	administration	(Striano	
et	al.,	2006).	It	seems	reasonable	to	relate	AEs	to	OXC	peak	concen-
tration	rather	than	to	the	active	metabolite	eslicarbazepine,	which	lev-
els	increase	more	slowly	(Keating,	2014).	ESL	is	directly	metabolized	to	
eslicarbazepine	with	minor	concentrations	of	r-	licarbazepine	and	OXC	
(Almeida	&	Soares-	Da-	silva,	2007).
At	 present,	 there	 is	 only	 one	 study	 documenting	 that	 overnight	
switch	from	OXC	to	ESL	seemed	to	be	safe	and	result	in	significant	im-
provements	in	AEs,	quality	of	life,	and	alertness	(Schmid	et	al.,	2016).	
However,	that	study	focused	on	acute	effects	following	the	transition	
leaving	long-	term	effects	of	such	transition	related	to	tolerability	and	
efficacy	still	unclear.
We	 provide	 3	month	 follow-	up	 data	 when	 transitioning	 patients	
with	focal	epilepsy	from	previous	OXC	treatment	to	ESL	in	a	standard-
ized	clinical	setting.	The	rationale	for	change	from	OXC	is	reported,	and	
3	month	outcome	with	respective	to	this	rationale	is	analyzed	in	terms	
of	tolerability	(the	main	objective)	and	efficacy	(the	secondary	objective).
2  | MATERIAL AND METHODS
We	 identified	all	 the	patients	 (age	at	 least	18	years)	with	 focal	epi-
lepsy	followed	in	the	Department	of	Neurology	in	Tampere	University	
Hospital,	 Finland	 from	 the	 patient	 registry.	 Following	 inclusion	 cri-
teria	were	applied:	(1)	current	treatment	with	OXC;	(2)	OXC-	related	
moderate	or	severe	tolerability	problems	which	affected	daily	life;	(3)	
transition	from	OXC	to	ESL	was	performed	due	to	OXC-	related	AEs;	
and	 (4)	 transition	was	 undertaken	 before	 30	November	 2015.	 The	
dosages	of	concomitant	AEDs	remained	unchanged	during	the	transi-
tion	period.	All	subjects	were	on	immediate-	release	OXC	as	extended-	
release	OXC	 is	 not	 available	 in	 Finland.	 Information	 on	 the	 patient	
characteristics	was	obtained	retrospectively	from	the	medical	records.
Tolerability	 problems	 related	 to	OXC	were	 categorized	 as	 in	 re-
cent	meta-	analysis	(Zaccara	et	al.,	2013)	addressing	neurological	AEs	
of	 new	 generation	 sodium-	blockers	 (somnolence,	 dizziness,	 vertigo,	
ataxia/coordination	 abnormal,	 diplopia,	 nystagmus,	 fatigue,	 tremor,	
headache,	 nausea,	 vomiting).	 Patients	 were	 classified	 according	 to	
ILAE	guidelines	to	temporal,	 frontal,	parietal,	occipital,	multifocal,	or	
unclassifiable	 epilepsies	 based	 on	 seizure	 characteristics,	 EEG	 and	
imaging	findings	and	for	some	patients	on	ictal	video-	EEG	recordings	
(CoCaTotILA,	 1989).	The	 etiologies	were	 divided	 into	 remote	 symp-
tomatic	and	unknown.	The	seizure	frequency	from	the	previous	year	
was	recorded;	seizure-	free	patients	did	not	have	any	seizures	during	
the	 previous	 year.	 Refractory	 epilepsy	 was	 defined	 as	 having	 per-
sistent	seizures	after	trials	of	at	least	two	AEDs	with	maximally	toler-
ated	doses	(sequentially	or	in	combination	therapy).
Patients	were	transitioned	overnight	from	OXC	to	ESL	in	a	hospital	
inpatient	setting	on	the	day	of	arrival	and	the	patients	were	followed	
up	 to	3	months	by	clinicians.	The	 target	dose	of	ESL	was	calculated	
using	an	OXC:ESL	dose	ratio	1:1	depending	on	the	pretransition	OXC	
dose.	If	the	1:1	dose	ratio	did	not	correspond	to	an	exact	ESL	dose,	
then	the	closest	lower	ESL	dose	was	used.	The	last	intake	of	OXC	was	
the	morning	dose	 followed	by	the	first	 intake	of	ESL	 in	 the	evening	
of	the	same	day.	After	1	and	3	months	an	evaluation	of	the	effects	of	
the	transition	was	made	in	terms	of	tolerability,	which	was	main	pur-
pose	of	this	study.	Efficacy	in	terms	of	seizure	change	was	evaluated	
at	1	and	3	months	after	transitioning.	All	AEs	and	their	intensity	(mild,	
moderate,	 severe)	were	 recorded	and	 reported	 following	 the	 transi-
tioning	period.	Mild	was	defined	as	 a	 symptom	not	 interfering	with	
daily	 activities,	moderate	as	 interfering	but	not	preventing	daily	 life	
activities	and	severe	as	incapacitating	at	least	part	of	daily	activities.	
Patients	were	dichotomied	by	outcome	in	terms	of	AEs	after	switched	
from	OXC	to	ESL.
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This	was	a	noninvasive,	retrospective	study,	which	does	not	oblige	
ethics	 committee	 approval	 according	 to	 Finnish	 Law	 on	 Research.	
Access	to	patient	records	based	on	decision	made	by	Head	of	Science	
Centre,	Tampere	University	Hospital	research	and	innovation	services,	
Science	Center.
3  | RESULTS
We	identified	23	patients,	who	were	transitioned	from	OXC	to	ESL	
because	 of	 OXC-	related	 AEs.	 Demographic	 and	medical	 character-
istic	 of	 the	 subjects	 are	 presented	 in	 Table	1.	 Three	most	 common	
concomitant	 AEDs	 were	 levetiracetam,	 topiramate,	 and	 clobazam.	
AEs	related	to	OXC	before	transition	to	ESL	are	described	in	Figure	1.	
Fifteen	(65.2%)	patients	OXC-	related	AEs	resolved	after	transition	at	
3	months	follow-	up	and	this	was	the	case	in	14	patients	at	1	month	
follow-	up.	Furthermore,	the	timing	of	the	AEs	over	the	day	with	re-
spect	 to	 their	 persistency	was	 analyzed	 and	 the	 results	 are	 shown	
in	Figure	2.	Two	 thirds	 (66.5%)	of	 the	AEs	occurred	 in	 the	morning	
and	most	of	 them	 (93.4%)	 resolved	after	 transitioning	OXC	 to	ESL.	
AEs	presenting	all	day	or	evening	tended	to	be	more	persistent	after	
transition.
The	most	intolerable	single	OXC-	related	AEs	were	somnolence,	
dizziness,	 and	 diplopia.	 Fatique,	 somnolence,	 tremor,	 diplopia,	
and	nausea	mostly	resolved	after	transition.	A	clear	tendency	that	
some	AEs	would	have	been	more	persistent	than	others,	especially	
in	 the	morning,	was	 not	 observed.	However,	 dizziness	 and	 coor-
dination	 problems	were	 the	 commonest	AEs	 that	 persisted	 after	 
transition.
The	effects	of	the	transition	from	OXC	to	ESL	on	seizure	frequency	
are	 summarized	 in	Table	2.	AEs	 occurring	 after	 transition	 related	 to	
ESL	are	shown	in	Figure	3.	The	incidence	of	AEs	was	higher	at	1	month	
(39.1%	[9/23])	than	at	3	month	follow-	up	(13.0%	[3/23]).	However,	no	
treatment	 discontinuations	 occurred	 and	 all	 patients	 continued	ESL	
throughout	the	study	period.	Most	of	the	AEs	attributed	to	ESL	were	
mild	and	some	moderate	in	intensity.	The	dose-	dependent	increase	in	
AEs	frequency	was	not	noticed.
Changes	 in	 seizure	 frequency	 or	 duration	 were	 not	 observed	
during	 the	 transition	 period	 in	 a	 hospital	 inpatient	 setting.	Two	pa-
tients	 reported	 headache	 during	 the	 hospitalization,	 but	 at	 1	 and	
3	month	 follow-	up	 this	AE	was	 not	 observed	 in	 these	 patients	 any	
more.	None	of	those	patients	who	had	AEs	during	the	follow-	up	did	
report	tolerability	problems	during	the	hospitalization.
TABLE  1 Demographic	and	medical	characteristics	of	the	patients
Number	of	patients 23
Sex
Female,	N	(%) 14	(60.9)
Male,	N	(%) 9	(39.1)
Mean	age;	years	(range) 41.8	(22–69)
Mean	duration	of	epilepsy;	years	(range) 14.4	(2–62)
Etiology
Remote	symptomatic,	N	(%) 17	(73.9)
Unknown,	N	(%) 6	(26.1)
Refractory	epilepsy,	N	(%) 18	(78.2)
Seizure	frequency
Seizure	free	(during	previous	year),	N	(%) 11	(47.8)
Persistent	seizures,	N	(%) 12	(52.2)
Mean	OXC	dose;	mg/day	(range) 1,152	(600–1,800)
Final	ESL	dose;	mg/day(range) 1,095	(800–2,000)
Number	of	concomitant	AEDs,	N	(%)
0 3	(13.0)
1 9	(39.2)
2 10	(43.5)
3 1	(4.3)
Number	of	prior	AEDs,	N	(%)
1 3	(13.0)
2 5	(21.8)
3 6	(26.1)
4 3	(13.0)
≥5 6	(26.1)
AEDs,	antiepileptic	drugs;	ESL,	eslicarbazepine	acetate;	OXC,	oxcarbazepine.
F IGURE  1 Adverse-	events	related	to	
oxcarbazepine.	One	or	more	adverse-	event	
can	be	present	on	a	single	subject
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4  | DISCUSSION
The	main	objective	of	this	study	transitioning	patients	with	focal	epi-
lepsy	from	OXC	to	ESL	due	to	typical	OXC-	related	AEs	was	to	evalu-
ate	the	tolerability	during	sufficiently	long	follow-	up	period.	Our	study	
demonstrates	that	patient	satisfaction	improved	significantly	in	terms	
of	reduced	AEs	after	switching	from	OXC	to	ESL	in	65%	of	the	sub-
jects	without	increase	in	seizure	frequency.	This	finding	is	similar	to	a	
previous	study	demonstrating	that	15	of	26	patients	who	were	tran-
sitioned	from	OXC	to	ESL	due	to	OXC-	related	AEs	no	longer	had	AEs	
after	 the	 change	 (Villanueva	 et	al.,	 2014).	 Furthermore,	we	 showed	
that	if	the	OXC-	related	AEs	are	most	evident	in	the	morning	(following	
morning	dosing),	nearly	all	of	them	(93%)	dissolved	after	transition	to	
ESL	indicating	a	relation	to	OXC	peak	cerebrospinal	fluid	and	plasma	
concentration	 as	 suggested	 earlier	 (Keating,	 2014).	 These	 findings	
might	help	clinician	in	everyday	practice	to	assess	whether	patient’s	
complaints	of	neurological	AEs	related	to	OXC,	especially	in	complex	
situations;	 several	 AEDs,	 comorbidities	 (e.g.	 depression,	 sleeping	
problems)	and,	persistent	seizures.
The	 secondary	 objective	was	 to	 assess	 the	 efficacy	 of	 ESL.	The	
results	 of	 this	 study	 indicated	 that	 when	 switched	 from	 OXC,	 ESL	
was	effective	 and	well	 tolerated	during	3	months	 follow-	up.	During	
previous	year	12	patients	had	persistent	seizures	and	after	changing	
from	OXC	to	ESL	 in	one	patient	 seizure	 frequency	 reduced	by	50%	
and	in	another	patient	by	30%.	Moreover,	in	two	patients	seizure	du-
ration	shortened	without	change	in	seizure	frequency.	Altogether	four	
patients	 of	 12	 achieved	 reduction	 in	 seizure	 frequency	or	 duration.	
Nevertheless,	the	fact	that	none	of	the	patients	had	increased	seizure	
frequency	is	at	least	as	important	as	seizure	reduction	in	small	propor-
tion	of	the	patients.
Earlier	expert	group′s	opinion	hypothesized	there	might	be	situ-
ations	 in	which	 it	may	be	 reasonable	 to	convert	patients	 from	OXC	
to	 ESL;	most	 appropriately	 those	who	 experience	OXC-	related	AEs	
or	have	poor	compliance	with	twice-	daily	OXC	dosing	(Peltola	et	al.,	
2015).	Recent	study	by	Schmid	et	al.	(2016)	demonstrated	that	over-
night	switching	from	OXC	to	ESL	was	safe	and	successful	with	regard	
to	efficacy	concerning	the	acute	and	immediate	effects	on	tolerability	
and	seizure	 issues.	Other	major	finding	 is	the	absence	of	seizure	re-
lated	or	other	problems	during	 the	 transition	 in	 any	of	our	patients	
which	 give	 added	 value	 to	 the	 publication	 by	 Schmid	 et	al.	 (2016).	
Furthermore,	we	 did	 not	 find	 any	 specific	 concerns,	why	 transition	
from	OXC	to	ESL	should	be	done	necessarily	in	an	inpatient	setting	as	
TABLE  2 The	effect	of	transition	from	oxcarbazepine	to	eslicarbazepine	acetate	on	seizure	frequency	in	3	month	follow-	up
Patient
Baseline SF (previous 
month) 1st month SF 2nd month SF 3rd month SF Outcome
1–11 Seizure	free No	seizures No	seizures No	seizures Still	seizure	free
12 1	SGS,	31	SPS,	4	CPS 30	SPS,	3	CPS 32	SPS,	4	CPS 31	SPS,	6	CPS No	significant	change	in	SF
13 Infrequent	seizuresa No	seizures No	seizures No	seizures No	significant	change	in	SF
14 1	SGS,	5	CPS 2	CPS No	seizures 1	CPS 50%	reduction	in	seizure	frequency
15 1	SPS,	2	CPS 2	SPS,	2	CPS 1	SPS,	3	CPS 1	SPS,	2	CPS No	significant	change	in	SF
16 83	SPS,	8	CPS 84	SPS,	8	CPS 83	SPS,	8	CPS 83	SPS,	8	CPS No	change	in	SF
17 5	CPS 4	CPS 5	CPS 6	CPS No	change	in	SF,	seizure	duration	shortened
18 1	CPS No	seizures 1	CPS No	seizures 30%	reduction	in	seizure	frequency
19 Infrequent	seizuresb No	seizures No	seizures No	seizures No	significant	change	in	SF
20 5	SPS,	8	CPS 5	SPS,	8	CPS 8	SPS,	11	CPS 7	SPS,	8	CPS No	change	in	SF,	CPS	seizure	duration	
shortened
21 1	SGS,	3	SPS,	1	CPS 1	SGS,	3	SPS,	3	
CPS
2	SPS,	2	CPS 1	SGS,	3	SPS,	1	
CPS
No	significant	change	in	SF
22 2	SGS,	7	CPS 3	SGS,	8	CPS 2	SGS,	11	CPS 3	SGS,	6	CPS No	significant	change	in	SF
23 1	SGS,	4CPS 1	CPS 4	CPS 2	SGS,	4	CPS No	significant	change	in	SF
CPS,	complex	partial	seizure;	SF,	seizure	frequency;	SGS,	secondary	generalized	tonic-	clonic	seizure;	SPS,	simple	partial	seizure.
a1	SGS	during	previous	year.
b1	CPS	during	previous	year.
F IGURE  2 Diurnal	variation	and	3	month	outcome	of	
oxcarbazepine-	related	adverse	events	after	transition	to	
eslicarbazepine	acetate
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done	earlier	in	our	center.	Transition	from	OXC	to	ESL	can	be	safely	
done	in	an	outpatient	setting.
There	were	slight	differences	how	the	prompt	switch	from	OXC	to	
ESL	was	conducted	in	our	center	in	comparison	to	the	previous	study	
by	Schmid	et	al.	(2016).	In	that	study	the	last	intake	of	OXC	was	the	
evening	dose	followed	by	first	intake	of	ESL	in	the	evening	of	next	day,	
whereas	 in	our	center	the	 last	 intake	of	OXC	was	the	morning	dose	
followed	by	the	first	intake	of	ESL	already	in	the	evening	of	the	same	
day.	There	were	no	differences	between	 these	 two	 studies	on	how	
the	initiation	of	ESL	was	performed	in	terms	of	target	dosing	as	both	
studies	aspired	to	use	a	ratio	of	1:1	of	OXC	and	ESL.
Considering	 the	 limitations,	 this	 was	 retrospective	 uncontrolled	
follow-	up	 study	 and	 the	 relative	 number	 of	 our	 patient	 is	 not	 high.	
However,	when	considering	the	results	and	conclusions	emerging	from	
our	study	the	number	of	patients	 is	 justified	as	 its’	present	 form.	The	
main	conclusion	is	that	such	OXC-	related	neurological	side-	effects	that	
appear	after	ingestion	of	the	morning	dose	of	OXC	disappear	in	the	vast	
majority	(over	90%)	of	the	patients	when	substituted	with	ESL,	whereas	
if	these	symptoms	exist	either	after	evening	dose	or	without	diurnal	vari-
ation	the	substitution	is	less	helpful.	This	association	is	so	strong	that	
the	current	number	of	patients	is	sufficient	to	provide	the	conclusion.
In	conclusion,	our	findings	support	 the	notion	 that	patients	cur-
rently	 receiving	OXC	and	 experiencing	 intolerable	AEs	 benefit	 from	
switching	 to	 ESL	 in	 order	 to	 maintain	 seizure	 control	 and	 improve	
AED	tolerability.	This	is	particularly	true	if	these	AEs	are	most	evident	
following	morning	dosing.	Our	data	also	suggest	that	transition	from	
OXC	to	ESL	can	be	performed	safely	in	an	outpatient	setting	instead	
of	overnight	hospitalization	for	cost	effectiveness	and	patient	comfort.
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